TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15598790
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of alcohol (control)
Study: 11829198
Drug: ISDN ointment
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ISDN ointment (13.4 +/- 3.61 mg ISDN)
Study: 9780281
Drug: Both G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both G‐CSF and rifabutin
Study: 8537705
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg orally
Study: 8537705
Drug: Rifampicin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin therapy
Study: 2320489
Drug: Sponging plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sponging plus acetaminophen
Study: 9115527
Drug: Acetaminophen alone
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen alone
Study: 656286
Drug: Digoxin solution
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin solution alone
Study: 656286
Drug: Three intact
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three intact capsules containing digoxin solution
Study: 656286
Drug: Three capsules
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three capsules containing digoxin solution sectioned in half
Study: 656286
Drug: Three capsules
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three capsules containing digoxin solution dissolved in water prior to administration
Study: 19568027
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of high-dose intravenous therapy followed by 3 weeks of oral therapy
Study: 19568027
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days or less intravenous treatment
Study: 19568027
Drug: Shortened course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortened course of intravenous and oral antibiotic therapy
Study: 14722627
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate (1000 mg/day for 12 weeks)
Study: 14722627
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1000 mg/day for 12 weeks)
Study: 7635409
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (IFN‐alpha) treatment
Study: 22315495
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day imatinib
Study: 22315495
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day imatinib
Study: 22315495
Drug: Imatinib C(min)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib C(min) > 1165 ng/mL on Day 29
Study: 19821004
Drug: 5% ethanolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% ethanolamine oleate after gelatin sponge administration (group E)
Study: 17585023
Drug: P125 (1.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: P125 (1.00 g protein x kg(‐1) x d(‐1))
Study: 17585023
Drug: P94 (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: P94 (0.75 g protein x kg(‐1) x d(‐1))
Study: 17585023
Drug: P63 (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: P63 (0.50 g protein x kg(‐1) x d(‐1))
Study: 14566492
Drug: Propofol anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anesthesia (5-10 mg.kg(‐1).h(‐1))
Study: 7790243
Drug: AHFX‐S: 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHFX‐S: 1.6 Gy/fraction, twice daily (6‐h interval), 5 days/week, total dose of 67.2 Gy/42 fractions/6 weeks
Study: 7790243
Drug: AFX‐C: 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFX‐C: 1.8 Gy/fraction/day, 5 daily fractions/week to 54 Gy/30 fractions/6 weeks, total dose of 70.5 Gy/41 fractions/6 weeks
Study: 2154086
Drug: Lisinopril plus
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril plus sodium restriction (low salt group)
Study: 2154086
Drug: Lisinopril plus
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril plus hydrochlorothiazide (diuretic group)
Study: 31385737
Drug: Integrated Psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Psychological Therapy (IPT) for Treatment-Resistant Schizophrenia (TRS)
Study: 31385737
Drug: Integrated Psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Psychological Therapy (IPT) for Nontreatment Resistant Schizophrenia (NTRS)
Study: 31385737
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) for Nontreatment Resistant Schizophrenia (NTRS)
Study: 31385737
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU) for Treatment-Resistant Schizophrenia (TRS)
Study: 27465911
Drug: 15 g soy
Normalized name: SOY ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g soy protein with 66 mg isoflavone (SPI)
Study: 27465911
Drug: 15 g soy
Normalized name: SOY ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g soy protein alone (SP)
Study: 23651878
Drug: MedON (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedON (with antiparkinsonian medication)
Study: 23651878
Drug: MedOFF (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedOFF (without antiparkinsonian medication)
Study: 15471991
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg daily dose of aspirin
Study: 15471991
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg daily dose of aspirin
Study: 15471991
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg daily dose of aspirin
Study: 15471991
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three aspirin doses
Study: 11697842
Drug: E7070 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7070 at 200 mg/m2/day
Study: 11697842
Drug: E7070 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7070 at 160 mg/m2/day
Study: 11697842
Drug: E7070 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7070 at 130 mg/m2/day
Study: 11697842
Drug: E7070 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7070 (various doses)
Study: 9593027
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg twice daily for 3 weeks)
Study: 9593027
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg twice daily for 12 months)
Study: 7930727
Drug: Immunization with
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunization with pneumococcal vaccine
Study: 3294594
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg three times a day)
Study: 3294594
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg three times a day) + Nifedipine (20 mg tablet twice a day)
Study: 3294594
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg tablet twice a day)
Study: 3294594
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg tablet twice a day) + Captopril (25 mg three times a day)
Study: 17889863
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (aspirin)
Study: 10389557
Drug: Subcutaneous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lignocaine
Study: 8550787
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (0.02 mg/kg BW.day, sc)
Study: 6308965
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ampicillin, methicillin, and netilmicin (AMN)
Study: 25846344
Drug: Celecoxib 6
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 6 mg·kg(‐1) preoperatively, followed by 3 mg·kg(‐1) twice daily for five doses
Study: 23078753
Drug: Maxillary sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary sinus lifting with autogenous bone augmentation and implant insertion at 6 months post grafting (Group I)
Study: 23078753
Drug: Maxillary sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary sinus lifting with autogenous bone augmentation mixed with PRP (Group II)
Study: 22048171
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 20/20F at Months 0,6 (n=240)
Study: 22048171
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 40/40F at Months 0,6 (n=241)
Study: 22048171
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 40/40F at Months 0,2 (n=240)
Study: 22048171
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 20/20F at Months 0,1,6 (licensed schedule, n=239)
Study: 19537094
Drug: Panavir (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panavir (monotherapy for chronic TBE; n = 30)
Study: 19537094
Drug: Panavir (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panavir (combined therapy for acute TBE; n = 113)
Study: 10381769
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg MDMA
Study: 25845448
Drug: Andolast 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andolast 2 mg t.i.d.
Study: 25845448
Drug: Andolast 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andolast 4 mg t.i.d.
Study: 25845448
Drug: Andolast 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andolast 8 mg t.i.d.
Study: 21451140
Drug: α(1)-blocker (prazosin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: α(1)-blocker (prazosin, 1 mg/20 kg body mass)
Study: 21451140
Drug: α(1)-blocker (prazosin)
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: α(1)-blocker (prazosin)
Study: 1539466
Drug: Recombinant B
Normalized name: Recombinant BCG Vaccine
DrugBank: VPM1002 (DB15801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant B subunit-whole cell cholera vaccine
Study: 1539466
Drug: Old type
Normalized name: Cheese, mold type specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old type B subunit-whole cell cholera vaccine
Study: 31789482
Drug: 25-hydroxy vitamin
Normalized name: 1α-hydroxy-vitamin D3
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxy vitamin D (25(OH)D) levels in the lowest tertile (<11 ng/mL)
Study: 31789482
Drug: FGF-23 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF-23 levels in the highest tertile (>3750 RU/mL)
Study: 30593883
Drug: Phenotype-stratified clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenotype-stratified clinical trial (Steroids in Eosinophil Negative Asthma - SIENA)
Study: 27937046
Drug: Trigger point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point dry needling in addition to personalized, evidence-based physical therapy treatment
Study: 27937046
Drug: Personalized, evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized, evidence-based physical therapy treatment
Study: 24929431
Drug: Liraglutide (GLP-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (GLP-1 receptor agonist)
Study: 355024
Drug: Placebo (tablets)
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablets)
Study: 11054648
Drug: Placebo (injections)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (injections)
Study: 6406435
Drug: Bupropion 300
Normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 300 mg/day
Study: 19947274
Drug: Chinese herb
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herb medicine of Gentongping (medicine group)
Study: 19947274
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (DAP and medicine)
Study: 17434847
Drug: Enfuvirtide-based therapy
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide-based therapy
Study: 15309728
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy combined with hyperthermia or activated carbon particles
Study: 12002878
Drug: Unilateral injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral injections of botulinum toxin
Study: 12002878
Drug: Bilateral injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral injections of botulinum toxin
Study: 8011011
Drug: Analgesic medications
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic medications
Study: 28408243
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg per day and bevacizumab 15 mg/kg every 21 days
Study: 23497601
Drug: CTC (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC (with reduced cathartic preparation and standard bowel preparation)
Study: 21473962
Drug: Prasugrel pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel pretreatment (30 mg after diagnosis + 30 mg at PCI)
Study: 21473962
Drug: Prasugrel non-pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel non-pretreatment (60 mg at PCI)
Study: 21473962
Drug: Prasugrel (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (5 or 10 mg daily)
Study: 19551471
Drug: Usual CC
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual CC
Study: 11226995
Drug: Oral isosmolar
Normalized name: Watersoluble, nephrotropic, high osmolar X-ray contrast media
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosmolar solution of electrolytes (ISE) administered at a volume of 4 mL/kg 3 hours before completing the fasting period
Study: 8989424
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms of immunogen (high dose)
Study: 8989424
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of immunogen (low dose)
Study: 3122517
Drug: Rivanol with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivanol with balloon catheter and oxytocin infusion
Study: 29915852
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion with sevoflurane anesthesia (Group S-M)
Study: 29915852
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion with desflurane anesthesia (Group D-M)
Study: 24472401
Drug: new combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: new combined formulation (olmesartan medoxomil + HCTZ)
Study: 24472401
Drug: co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-administration of separate tablets (reference drugs)
Study: 22334811
Drug: Open-label fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label fluoxetine (FLX)
Study: 21102998
Drug: Gaboxadol 15
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol 15 mg (GBX)
Study: 21102998
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg (ZOL)
Study: 18203893
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g EPA plus high-oleic sunflower oil (HOS)
Study: 16437727
Drug: Amoxicillin, clarithromycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, clarithromycin, lansoprazole (Group 1)
Study: 12939213
Drug: Abciximab treatment
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab treatment (n=1052)
Study: 12939213
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no abciximab treatment, n=1030)
Study: 10999156
Drug: Granulocyte macrophage
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte macrophage colony stimulating factor (GMCSF) 150 mcg subcutaneously 24 hours prior to vaccination
Study: 10999156
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received standard three doses of 40 mcg hepatitis B vaccine monthly
Study: 8697829
Drug: Prednisone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.75 mg/kg/d for up to 4 weeks with gradual reduction over an additional 2 weeks)
Study: 24247275
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention (INT) including pharmacist-led medication reconciliation, patient education, collaborative care, and voice messaging.
Study: 24247275
Drug: Multifaceted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifaceted intervention (INT) for β-blockers adherence.
Study: 22947594
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate long-acting injection (PP-LAI)
Study: 15187573
Drug: Quinapril (high-tissue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (high-tissue penetrating ACE inhibitor)
Study: 15187573
Drug: Enalapril (low-tissue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (low-tissue penetrating ACE inhibitor)
Study: 10489384
Drug: Domperidone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (20 mg orally)
Study: 1945319
Drug: Programs that
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programs that determine thresholds only twice at a given location
Study: 7021041
Drug: L-dopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (500 mg, orally)
Study: 7021041
Drug: L-dopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (100 mg, orally) plus carbidopa (35 mg, orally) after pretreatment with carbidopa (50 mg every 6 h for four doses)
Study: 24472224
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet formulations of azithromycin and chloroquine (AZCQ) administered at approximately 30 mg/kg AZ and 10 mg/kg CQ once daily for 3 days in children.
Study: 24472224
Drug: Two AZCQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two AZCQ tablets (AZ/CQ 250/155 mg per tablet) in adults.
Study: 24472224
Drug: Individual commercial
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual commercial tablets of azithromycin 500 mg and chloroquine 300 mg in adults.
Study: 22318278
Drug: 4CMenB at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB at 2, 4, and 6 months with routine vaccines
Study: 22318278
Drug: 4CMenB at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB at 2, 4, and 6 months without routine vaccines
Study: 22318278
Drug: 4CMenB with
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB with routine vaccines at 2, 3, and 4 months
Study: 22318278
Drug: Routine vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine vaccines alone at 2, 3, and 4 months
Study: 22318278
Drug: 4CMenB doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB doses administered alone
Study: 22318278
Drug: Routine vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine vaccines given alone
Study: 22318278
Drug: 4CMenB and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB and routine vaccines administered together
Study: 20705156
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg misoprostol
Study: 20705156
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg misoprostol
Study: 17337887
Drug: ASA +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA + extended-release dipyridamole (DP)
Study: 9523035
Drug: High vitamin
Normalized name: Super High Vitamins and Minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: High vitamin E supplements
Study: 15485475
Drug: Oral methionine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine, 100 mg kg(‐1) in fruit juice
Study: 15485475
Drug: Oral methionine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine, 100 mg kg(‐1) in fruit juice plus antioxidant vitamin E, 800 IU, and ascorbic acid, 1000 mg
Study: 11568905
Drug: Vincristine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine administration
Study: 9623632
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg paroxetine (T II)
Study: 9623632
Drug: 21 g
Normalized name: Long's Lancets, 21 ga
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 g branched-chain amino acids (BCAA) (T III)
Study: 9623632
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g tyrosine (TYR) (T IV)